The results showed that iRGD-modified nanoparticles were enriched in tumor sites, inhibiting the tumor proliferation and also up-regulating the differentiation of cytotoxic CD8+ T cells, confirming that the integrin-targeting nanoparticles can activate the immune response against tumor (Figure 6). This evidence concerns the gene CD8A and neoplasm.